JP3340928B2 - Melanin production inhibitor and whitening cosmetic - Google Patents
Melanin production inhibitor and whitening cosmeticInfo
- Publication number
- JP3340928B2 JP3340928B2 JP35617996A JP35617996A JP3340928B2 JP 3340928 B2 JP3340928 B2 JP 3340928B2 JP 35617996 A JP35617996 A JP 35617996A JP 35617996 A JP35617996 A JP 35617996A JP 3340928 B2 JP3340928 B2 JP 3340928B2
- Authority
- JP
- Japan
- Prior art keywords
- melanin production
- present
- melanin
- production inhibitor
- whitening cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000008099 melanin synthesis Effects 0.000 title claims description 22
- 239000002537 cosmetic Substances 0.000 title claims description 18
- 230000002087 whitening effect Effects 0.000 title claims description 13
- 239000003112 inhibitor Substances 0.000 title claims description 12
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 16
- 229930182470 glycoside Natural products 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 208000012641 Pigmentation disease Diseases 0.000 description 13
- 150000002338 glycosides Chemical class 0.000 description 13
- 206010014970 Ephelides Diseases 0.000 description 10
- 208000003351 Melanosis Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000019612 pigmentation Effects 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 229960000271 arbutin Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 4
- -1 raspberry ketone glycoside Chemical class 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 230000003061 melanogenesis Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- 150000005208 1,4-dihydroxybenzenes Chemical class 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SFUCGABQOMYVJW-UHFFFAOYSA-N 4-(4-Hydroxyphenyl)-2-butanol Chemical compound CC(O)CCC1=CC=C(O)C=C1 SFUCGABQOMYVJW-UHFFFAOYSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000383403 Solen Species 0.000 description 1
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 description 1
- UAOKXEHOENRFMP-ZJIFWQFVSA-N [(2r,3r,4s,5r)-2,3,4,5-tetraacetyloxy-6-oxohexyl] acetate Chemical compound CC(=O)OC[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)C=O UAOKXEHOENRFMP-ZJIFWQFVSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 150000003613 toluenes Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Landscapes
- Cosmetics (AREA)
Description
【0001】[0001]
【発明の属する技術分野】本発明は、メラニン生成抑制
剤、ならびにそれを含有した美白化粧料に関する。さら
に詳しくは、安全性が高く、化粧品、医薬部外品および
医薬品などに、紫外線に曝露されたことによって生じた
皮膚の色素沈着(しみ、そばかすなど)を改善する効果
を目的として配合できるメラニン生成抑制剤に関する。TECHNICAL FIELD The present invention relates to a melanin production inhibitor and a whitening cosmetic containing the same. More specifically, melanin production is highly safe and can be combined with cosmetics, quasi-drugs, and pharmaceuticals for the purpose of improving skin pigmentation (stains, freckles, etc.) caused by exposure to ultraviolet light. Related to inhibitors.
【0002】[0002]
【従来の技術】しみ、そばかすは、メラニンの生成と排
泄のバランスが崩れ、表皮細胞内にメラニンが過剰に蓄
積したものである〔三島豊他、フレグランスジャーナ
ル、17(1)、p25、1989〕。これらの原因
は、炎症、ホルモンのバランス、遺伝的要因などさまざ
まであるが、紫外線の影響により助長される。増加した
色素沈着を緩和するのが美白剤である。このうち、美白
化粧品用に応用されているものとしては、アスコルビン
酸またはその誘導体、プラセンタエキス、ハイドロキノ
ン誘導体(アルブチン)、コウジ酸等が知られており、
これらを配合した美白化粧料が提案されている。BACKGROUND ART Spots and freckles are those in which the balance between production and excretion of melanin is lost and melanin is excessively accumulated in epidermal cells [Yutaka Mishima et al., Fragrance Journal, 17 (1), p25, 1989]. . These causes can be varied, including inflammation, hormonal balance, and genetic factors, but are facilitated by the effects of ultraviolet radiation. Whitening agents alleviate the increased pigmentation. Among them, ascorbic acid or its derivatives, placenta extract, hydroquinone derivative (arbutin), kojic acid, etc. are known as those applied for whitening cosmetics.
Whitening cosmetics containing these compounds have been proposed.
【0003】しかし、これらの美白剤は、メラニンの生
成を抑制する効果はあるものの、安全性に問題を残すも
のが多かった。さらに、これらの美白剤を配合した美白
化粧料を塗布しても、しみ、そばかすの改善において必
ずしも十分満足すべき効果が得られなかった。[0003] However, although these whitening agents have an effect of suppressing the production of melanin, many of them have a problem in safety. Further, even when a whitening cosmetic containing these whitening agents is applied, a sufficiently satisfactory effect in improvement of spots and freckles was not necessarily obtained.
【0004】メラニンは、表皮基底層にあるメラノサイ
ト(色素細胞)内の細胞小器官であるメラノソームで生
成される。その後、ケラチノサイト(表皮細胞)へ受け
渡され、ケラチノサイト内で分解を受けながら角化の流
れに乗り、最終的には角化細胞の落屑とともに皮膚から
消失する(清寺真、現代皮膚科学大系、3B、97頁、
中山書店、1982)。[0004] Melanin is produced by melanosomes, the organelles in melanocytes (pigment cells) in the basal layer of the epidermis. After that, it is transferred to keratinocytes (epidermal cells), rides on the flow of keratinization while undergoing decomposition within the keratinocytes, and finally disappears from the skin with desquamation of the keratinocytes (Masayoshi Kiyoji, a modern dermatologist, 3B, 97 pages,
Nakayama Shoten, 1982).
【0005】したがって、しみ、そばかすの原因は、複
雑であるので、単にメラニンの生成を抑制するのみでな
く、色素沈着の原因となる炎症を防止したり、新陳代謝
を活発化することによりメラニンが皮膚内部に留まるこ
とを防止したり、紫外線等によってダメージを受けた皮
膚機能を回復させたりすることが重要である。[0005] Therefore, since the cause of spots and freckles is complex, melanin not only suppresses the production of melanin, but also prevents inflammation which causes pigmentation and activates metabolism to cause melanin to develop in the skin. It is important to prevent it from staying inside and to restore skin function damaged by ultraviolet rays or the like.
【0006】[0006]
【発明が解決しようとする課題】本発明の目的は、安全
性が高く、優れたメラニン生成抑制作用を有するメラニ
ン生成抑制剤を提供するとともに、紫外線に曝露された
ことによって生じた皮膚の色素沈着(しみ、そばかすな
ど)を改善する効果に優れた美白化粧料を提供すること
にある。SUMMARY OF THE INVENTION An object of the present invention is to provide a melanin production inhibitor which is highly safe and has an excellent melanin production inhibitory action and, at the same time, pigmentation of skin caused by exposure to ultraviolet rays. An object of the present invention is to provide a whitening cosmetic having an excellent effect of improving (spots, freckles, etc.).
【0007】[0007]
【課題を解決するための手段】本発明者らは、上記事情
を鑑み、メラニン生成抑制効果を有し、かつ高い安全性
を有するメラニン生成抑制剤を開発すべく鋭意検討した
結果、特定の配糖体が強いメラニン生成抑制作用と、紫
外線に曝露されたことによって生じた皮膚の色素沈着
(しみ、そばかすなど)を改善する効果も共に有してい
ることを見いだし、本発明を完成した。すなわち、本発
明は、下記一般式で示される特定の配糖体およびそれを
含有することを特徴とする美白化粧料である。Means for Solving the Problems In view of the above circumstances, the present inventors have conducted intensive studies to develop a melanin production inhibitor having a melanin production inhibitory effect and having high safety. The present inventors have found that a saccharide has both a strong melanin production inhibitory effect and an effect of improving skin pigmentation (stains, freckles, etc.) caused by exposure to ultraviolet rays, and completed the present invention. That is, the present invention is a specific glycoside represented by the following general formula, and a whitening cosmetic containing the same.
【0008】[0008]
【化2】 Embedded image
【0009】(但し、式中Rは単糖類、二糖類の残基か
ら選ばれる基である。)(Where R is a group selected from the residues of monosaccharides and disaccharides )
【0010】[0010]
【発明の実施の形態】以下、本発明の実施の形態につい
て詳述する。Embodiments of the present invention will be described below in detail.
【0011】本発明に用いられる配糖体の一部は公知の
物質である(フィトケミストリィ、第29巻、第12
号、3853頁、1990年)が、報告された公知物質
にメラニン生成抑制作用を有することについては、何ら
記載が無い。Some of the glycosides used in the present invention are known substances (Phytochemistry, Vol. 29, No. 12).
No., p. 3853, 1990) does not disclose that the reported known substance has a melanin production inhibitory action.
【0012】本発明の配糖体を得る方法としては、アル
ブチンの合成方法として既に公知の方法(USP第32
01385号)を用いて得ることができる。例えば、ト
ルエンなどの有機溶媒中において4−(p−ヒドロキシ
フェニル)−2−ブタノール(以下、ロドデンドロール
と略す)とアセチル化糖を三フッ素化ホウ素やオキシ塩
化リンなどを触媒として縮合した後、アルカリ存在下に
アセチル基を脱離することにより本発明の配糖体を白色
の粉末結晶として容易に得ることができる。また、ラズ
ベリーケトングリコシドを還元することによっても得る
こともできる。さらに、天然物から単離することも可能
である。なお、本発明の配糖体には、光学異性体が存在
するが、(+)体、(−)体単独でも、またそれらの混
合物〔(±)と表記する、特開平3−251548号公
報〕を用いることもできる。As a method for obtaining the glycoside of the present invention, a method already known as a method for synthesizing arbutin (USP No. 32)
No. 01385). For example, after condensing 4- (p-hydroxyphenyl) -2-butanol (hereinafter abbreviated as rhodendrol) and acetylated sugar in an organic solvent such as toluene using boron trifluoride or phosphorus oxychloride as a catalyst, By removing the acetyl group in the presence of an alkali, the glycoside of the present invention can be easily obtained as white powdery crystals. It can also be obtained by reducing raspberry ketone glycoside. Furthermore, it is also possible to isolate from natural products. Although the glycoside of the present invention has optical isomers, it may be (+)-form or (-)-form alone or a mixture thereof (referred to as JP-A-3-251548). ] Can also be used.
【0013】本発明で用いられる糖残基は、還元性の単
糖類または二糖類であり、具体的にはグルコース、ガラ
クトース、キシロース、マンノース、N−アセチルグル
コサミン等の単糖類、マルとース、セロビオース、ゲン
チビオース等の二糖類を挙げることができる。本発明の
配糖体にはα結合およびβ結合を有する異性体が存在す
るが、単独でも、またそれらの混合物を用いることもで
きる。The sugar residue used in the present invention is a reducing monosaccharide or disaccharide , and specifically, monosaccharides such as glucose, galactose, xylose, mannose, N-acetylglucosamine, maltose, cellobiose, mention may be made of a disaccharide such as gentibiose. The glycoside of the present invention has isomers having an α bond and a β bond, but may be used alone or in a mixture thereof.
【0014】本発明で用いられる具体的な配糖体は、ロ
ドデンドロール−D−グルコシド(αおよびβ体)、ロ
ドデンドロール−D−ガラクトシド(αおよびβ体)、
ロドデンドロール−D−キシロシド(αおよびβ体)、
ロドデンドロール−D−マルトシド(αおよびβ体)な
どの、(+)体・(−)体・(±)を挙げることができ
る。これらの内、入手の容易さ・天然界に存在する・美
白効果が高いことなどから、(+)−ロドデンドロール
−D−グルコシド(β体)が最も好ましい。Specific glycosides used in the present invention include rhododendrol-D-glucoside (α and β forms), rhododendol-D-galactoside (α and β forms),
Rhododendrol-D-xyloside (α and β forms),
(+)-Form, (-)-form, (±) such as rhododendrol-D-maltoside (α- and β-forms). Of these, (+)-rhodendrol-D-glucoside (β-form) is most preferred because of its availability, existence in the natural world, and high whitening effect.
【0015】本発明のメラニン生成抑制剤は、医薬品・
医薬部外品・化粧品などに配合することができる。特
に、色素沈着を改善する美白化粧料に配合することが好
適である。なお、本発明のメラニン生成抑制剤は、外用
組成物あるいは内服用組成物にも配合できる。The melanin production inhibitor of the present invention is used
It can be incorporated into quasi-drugs and cosmetics. In particular, it is suitable to be incorporated into a whitening cosmetic which improves pigmentation. In addition, the melanin production inhibitor of the present invention can be blended into a composition for external use or a composition for internal use.
【0016】本発明のメラニン生成抑制剤の配合量は使
用する系によって様々で、一概には言えないが、以下の
実施例から明らかなように、既存のこの種の物質と同等
もしくはかなり低濃度でよく、0.05〜10.0重量
%を用いることができる。The amount of the melanogenesis inhibitor of the present invention varies depending on the system to be used, and cannot be specified unconditionally. And 0.05 to 10.0% by weight can be used.
【0017】本発明の美白化粧料には、必要に応じて、
通常、医薬品、医薬部外品、化粧品等の皮膚外用剤に配
合される油脂類、保湿剤類、顔料類、色素類、界面活性
剤類、抗酸化剤類、紫外線吸収剤類、防腐剤類、水溶性
高分子類、樹脂類等を適宜配合することができる。In the whitening cosmetic of the present invention, if necessary,
Oils and fats, moisturizers, pigments, pigments, surfactants, antioxidants, ultraviolet absorbers, preservatives, which are usually incorporated in skin external preparations such as pharmaceuticals, quasi-drugs, and cosmetics And water-soluble polymers, resins and the like can be appropriately compounded.
【0018】また、軟膏類、ローション類、乳液類、ク
リーム類、パック類、顆粒類等の任意の剤型とすること
ができる。Further, it can be in any dosage form such as ointments, lotions, emulsions, creams, packs, granules and the like.
【0019】[0019]
【実施例】次に、本発明の配糖体によるメラニン生成抑
制作用の効果を明らかにするための実施例として、合成
例、試験例、配合製剤例(美白化粧料)を示す。EXAMPLES Next, as examples for clarifying the effect of the glycoside of the present invention on the inhibitory action of melanin production, synthetic examples, test examples and blended preparation examples (whitening cosmetics) will be shown.
【0020】合成例1:(±)−ロドデンドロール−D
−グルコシドの合成 合成方法の具体例として、以下にロドデンドロール−D
−グルコシドの合成方法を示すが、本発明で用いるメラ
ニン生成抑制剤を合成する方法はこの限りではない。Synthesis Example 1: (±) -Rhodendrol-D
-Synthesis of glucoside As a specific example of the synthesis method, rhododendrol-D
A method for synthesizing a glucoside will be described, but the method for synthesizing the melanin production inhibitor used in the present invention is not limited thereto.
【0021】40mlの脱水トルエンと、10mlの脱水エ
チルエーテルの混合溶液に2.76g (16.6mmo
l)の(±)−ロドデンドロール、8g (20mmo
l)のグルコースペンタアセテート、モレキュラーシー
ブス2g を入れ、室温下に約1時間撹拌した後、三フッ
素化ホウ素ジエチルエーテル溶液1mlを加え、さらに3
時間撹拌した。20mlの水を加えた後、モレキュラーシ
ーブスをろ別した。ろ液から酢酸エチルで有機層を抽出
した。酢酸エチル層を1N水酸化ナトリウムで洗浄し、
未反応の(±)−ロドデンドロールを除去した。酢酸エ
チル層を精製水で洗浄した後、硫酸ナトリウムで乾燥し
た。硫酸ナトリウムを除去した後、減圧下に有機溶媒を
除去することにより、(±)−ロドデンドロールテトラ
アセチル−D−グルコシドを得た。2.76 g (16.6 mmol) was added to a mixed solution of 40 ml of dehydrated toluene and 10 ml of dehydrated ethyl ether.
1) (±) -Rhodendrol, 8 g (20 mmo)
l) Glucose pentaacetate and 2 g of molecular sieves were added, and the mixture was stirred at room temperature for about 1 hour.
Stirred for hours. After adding 20 ml of water, the molecular sieves were filtered off. The organic layer was extracted from the filtrate with ethyl acetate. Washing the ethyl acetate layer with 1N sodium hydroxide,
Unreacted (±) -rhodendrol was removed. The ethyl acetate layer was washed with purified water and dried over sodium sulfate. After removing sodium sulfate, the organic solvent was removed under reduced pressure to obtain (±) -rhodendrol tetraacetyl-D-glucoside.
【0022】得られたアセチル体を常法に従って、ナト
リウムメトキシドを用いて、脱アセチル化をした後、イ
オン交換樹脂(アンバーライト)を用いて中和した。イ
オン交換樹脂をろ別した後、減圧下に溶媒を除去し、
(±)−ロドデンドロール−D−グルコシド(β体)
3.8g を得た。この構造は13C−NMRスペクトルお
よび赤外吸収スペクトルにより確認した。図1に本発明
で得た(±)−ロドデンドロール−D−グルコシド(β
体)の、13C−NMRスペクトルを示す。The obtained acetyl form was deacetylated with sodium methoxide according to a conventional method, and then neutralized with an ion exchange resin (Amberlite). After filtering off the ion exchange resin, the solvent was removed under reduced pressure,
(±) -Rhodendrol-D-glucoside (β form)
3.8 g were obtained. This structure was confirmed by a 13 C-NMR spectrum and an infrared absorption spectrum. FIG. 1 shows (±) -rhodendrol-D-glucoside (β
2 shows a 13 C-NMR spectrum of the compound (I).
【0023】なお、合成例1に準じて、表1の「試料」
欄に示す、本発明に係わる、配糖体を得た。In addition, according to Synthesis Example 1, "Sample" in Table 1 was used.
Glycosides according to the present invention shown in the column were obtained.
【0024】試験例1:メラニン生成抑制試験〔インビ
トロ(in vitro)試験〕 色素細胞でのメラニン生成抑制試験は、B16メラノー
マ細胞(3×105 個)を直径90mmのプラスチックプ
レートにまき、同時に試験試料を3×10-5M濃度(試
験濃度はモル濃度に統一した)で添加し、72時間培養
を行った。培養は10%FBSを含むMEM(2mMテ
オフィリン含有)培地で行った。培養終了後、常法に従
って、細胞を剥離し洗浄を行った後、遠心分離を行っ
た。得られた細胞を5%TCA、エタノール:エーテル
=3:1、さらにエーテルの順に洗浄した。乾燥後、ソ
ルエン350に溶解し400nmにて吸光度測定するこ
とにより、メラニン量を測定した。吸光度が低い程、メ
ラニン生成抑制効果が大きいことを示す。なお、比較例
として、メラニン生成抑制効果を有していることが知ら
れているハイドロキノン配糖体(アルブチン)を用い
た。Test Example 1 Melanin Production Inhibition Test [In Vitro Test] In the melanin production inhibition test using pigment cells, B16 melanoma cells (3 × 10 5 cells) were spread on a 90 mm diameter plastic plate and tested simultaneously. The sample was added at a concentration of 3 × 10 −5 M (the test concentration was unified to the molar concentration), and the cells were cultured for 72 hours. The culture was performed in a MEM (containing 2 mM theophylline) medium containing 10% FBS. After completion of the culture, the cells were detached and washed according to a conventional method, and then centrifuged. The obtained cells were washed with 5% TCA, ethanol: ether = 3: 1, and then with ether. After drying, the melanin content was measured by dissolving in Solen 350 and measuring the absorbance at 400 nm. The lower the absorbance, the greater the melanin production inhibitory effect. As a comparative example, a hydroquinone glycoside (arbutin) known to have a melanin production inhibitory effect was used.
【0025】測定結果を表1に示す。Table 1 shows the measurement results.
【0026】[0026]
【表1】 [Table 1]
【0027】表1の結果から、本発明のメラニン生成抑
制剤は、細胞の増殖を妨げることなく(安全性が高いこ
とを意味する)、メラニン生成を抑制することが明らか
になった。また、その程度は医薬品・化粧品等に汎用さ
れているアルブチンに比べて吸光度が低く、すなわちメ
ラニン生成抑制効果に優れていることが判った。この、
インビトロ試験成績より、本発明の特定の配糖体は、美
白化粧料の主剤として、例えば医薬品、医薬部外品、化
粧品などに配合することが可能であることが、再確認で
きた。From the results shown in Table 1, it was clarified that the melanin production inhibitor of the present invention inhibits melanin production without inhibiting cell proliferation (meaning high safety). In addition, it was found that the degree of absorbance was lower than that of arbutin, which is widely used in pharmaceuticals, cosmetics, and the like, that is, the melanin production inhibitory effect was excellent. this,
From the results of the in vitro test, it was reconfirmed that the specific glycoside of the present invention can be added to, for example, pharmaceuticals, quasi-drugs, cosmetics, and the like as a main component of whitening cosmetics.
【0028】試験例2:皮膚色素沈着回復試験〔インビ
ボ(in vivo) 試験〕 被験者一群20名の上腕内側部皮膚に、紫外線照射部位
を2ケ 所設定(2×2cm)し、最小紅斑量の中波長領域
紫外線(デルマレイN−DMR型、東芝医療用品製)を
3日間連続照射した。照射終了後より、一方には試料製
剤を1日3回ずつ4週間連続で塗布し、他方にはベース
(本製剤から主剤を除いたもの)を塗布した。紫外線照
射から4週間後にそれぞれの部分を肉眼判定により、ベ
ース塗布部と試料製剤塗布部の色素沈着の程度の比較を
行った。表2の評価基準により、ベース塗布部と比較し
て色素沈着の回復度を評価した。なお、評価は20名の
評価点の平均値で示す。Test Example 2: Skin Pigmentation Recovery Test [In Vivo Test] Two ultraviolet irradiation sites (2 × 2 cm) were set on the inner skin of the upper arm of a group of 20 subjects, and the minimum erythema amount was measured. Irradiation was performed continuously for 3 days with ultraviolet rays in the middle wavelength region (Dermalei N-DMR, manufactured by Toshiba Medical Products). From the end of the irradiation, one was coated with the sample preparation three times a day for four consecutive weeks, and the other was coated with the base (the main preparation was removed from the preparation). Four weeks after the ultraviolet irradiation, the degree of pigmentation between the base application part and the sample preparation application part was compared by visual judgment of each part. According to the evaluation criteria in Table 2, the degree of recovery of pigmentation was evaluated in comparison with the base coated part. In addition, evaluation is shown by the average value of the evaluation point of 20 persons.
【0029】[0029]
【表2】 [Table 2]
【0030】実施例1〜3、比較例1(クリーム) 表3における処方で、常法に従ってクリームを作製し
た。Examples 1 to 3 and Comparative Example 1 (Cream) Creams were prepared according to the recipe shown in Table 3 according to a conventional method.
【0031】[0031]
【表3】 [Table 3]
【0032】実施例1〜3、比較例1の皮膚色素沈着回
復試験の結果を表4に示す。Table 4 shows the results of the skin pigmentation recovery tests of Examples 1 to 3 and Comparative Example 1.
【0033】[0033]
【表4】 [Table 4]
【0034】表4から、本発明の実施例は、しみ、そば
かすを改善する効果に優れることは明らかである。特
に、(+)−ロドデンドロール−D−グルコシド(β
体)を配合した、実施例1は効果が顕著であった。な
お、試験期間中、被験者の試料製剤塗布部位に皮膚刺激
反応は認められず、本発明品は製剤の形態においても安
全であることが確認できた。From Table 4, it is clear that the examples of the present invention are excellent in the effect of improving spots and freckles. In particular, (+)-rhodendrol-D-glucoside (β
Example 1 in which the compound of formula (1) was blended, had a remarkable effect. During the test period, no skin irritation reaction was observed at the site where the sample preparation was applied to the test subject, confirming that the product of the present invention is safe even in the form of the preparation.
【0035】実施例4(乳液) 表5における処方で、常法に従って乳液を作製した。Example 4 (Emulsion) An emulsion was prepared according to the formulation shown in Table 5 according to a conventional method.
【0036】[0036]
【表5】 [Table 5]
【0037】実施例5(化粧水) 表6における処方で、常法に従って化粧水を作製した。Example 5 (Lotion) A lotion was prepared according to the formulation shown in Table 6 according to a conventional method.
【0038】[0038]
【表6】 [Table 6]
【0039】実施例4〜5の皮膚色素沈着回復試験の結
果を表7に示す。Table 7 shows the results of the skin pigmentation recovery tests of Examples 4 and 5.
【0040】[0040]
【表7】 [Table 7]
【0041】表7から、実施例4〜5は、しみ、そばか
すの改善効果に優れることは明らかである。From Table 7, it is clear that Examples 4 and 5 are excellent in the effect of improving spots and freckles.
【0042】[0042]
【発明の効果】以上記載のように、本発明の配糖体は、
優れたメラニン生成抑制作用を示し、またその安全性も
高かった。さらに、本発明の配糖体を配合した製剤は、
紫外線に曝露されたことによって生じた皮膚の色素沈着
(しみ、そばかすなど)を改善する優れた効果を示し
た。したがって、本発明の配糖体は、紫外線などによる
メラニンの過剰生成によるしみ、そばかすなどの形成を
予防する化粧品や医薬部外品への配合、色素沈着症の治
療、予防剤としての薬品への利用が可能な、有用なメラ
ニン生成抑制剤を提供することは明かである。As described above, the glycoside of the present invention comprises
It exhibited an excellent melanin production inhibitory effect, and its safety was also high. Further, the formulation containing the glycoside of the present invention,
It showed an excellent effect of improving skin pigmentation (stains, freckles, etc.) caused by exposure to UV light. Therefore, the glycosides of the present invention can be used in cosmetics and quasi-drugs to prevent the formation of spots, freckles, etc. due to excessive production of melanin by ultraviolet rays, treatment of pigmentation, Clearly, it provides useful melanogenesis inhibitors that can be utilized.
【図1】本発明の合成例1で得られた(±)−ロドデン
ドロール−D−グルコシド(β体)の13C−NMRスペ
クトルを示す図である。FIG. 1 is a view showing a 13 C-NMR spectrum of (±) -rhodendrol-D-glucoside (β-form) obtained in Synthesis Example 1 of the present invention.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平10−17462(JP,A) 特開 平9−241128(JP,A) 特開 平8−133957(JP,A) 特開 平8−20524(JP,A) 特開 平6−199649(JP,A) 特開 平6−256137(JP,A) 特開 平6−107536(JP,A) 特開 平5−201846(JP,A) 特開 平4−59718(JP,A) 特開 平10−182476(JP,A) 特開 平5−123175(JP,A) 特開 平2−211891(JP,A) 特開 平3−251548(JP,A) (58)調査した分野(Int.Cl.7,DB名) A61K 7/00 - 7/50 CA(STN) REGISTRY(STN)────────────────────────────────────────────────── ─── Continuation of the front page (56) References JP-A-10-17462 (JP, A) JP-A-9-241128 (JP, A) JP-A 8-133957 (JP, A) JP-A 8- 20524 (JP, A) JP-A-6-199649 (JP, A) JP-A-6-256137 (JP, A) JP-A-6-107536 (JP, A) JP-A-5-201846 (JP, A) JP-A-4-59718 (JP, A) JP-A-10-182476 (JP, A) JP-A-5-123175 (JP, A) JP-A-2-2121891 (JP, A) JP-A-3-251548 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 7/ 00-7/50 CA (STN) REGISTRY (STN)
Claims (2)
である。)からなるメラニン生成抑制剤。[Claim 1] The following general formula: (Wherein, R is a group selected from the residues of monosaccharides and disaccharides ).
含有することを特徴とする美白化粧料。2. A whitening cosmetic comprising the melanin production inhibitor according to claim 1.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35617996A JP3340928B2 (en) | 1996-12-24 | 1996-12-24 | Melanin production inhibitor and whitening cosmetic |
| TW86115777A TW464501B (en) | 1996-12-17 | 1997-10-24 | Melanine formation inhibitor and their beautiful-white cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP35617996A JP3340928B2 (en) | 1996-12-24 | 1996-12-24 | Melanin production inhibitor and whitening cosmetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10182410A JPH10182410A (en) | 1998-07-07 |
| JP3340928B2 true JP3340928B2 (en) | 2002-11-05 |
Family
ID=18447732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP35617996A Expired - Lifetime JP3340928B2 (en) | 1996-12-17 | 1996-12-24 | Melanin production inhibitor and whitening cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3340928B2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4871782B2 (en) * | 2006-09-01 | 2012-02-08 | 花王株式会社 | Topical skin preparation |
| JP5049638B2 (en) * | 2007-04-26 | 2012-10-17 | 花王株式会社 | Topical skin preparation |
| JPWO2009081587A1 (en) * | 2007-12-25 | 2011-05-06 | 花王株式会社 | Skin preparation |
| WO2009084200A1 (en) * | 2007-12-27 | 2009-07-09 | Kao Corporation | External skin preparation for pimpled skin |
| WO2010041417A1 (en) * | 2008-10-07 | 2010-04-15 | 花王株式会社 | External preparation for skin |
| JP6432114B2 (en) * | 2014-12-25 | 2018-12-05 | 有限会社イムノ | Drugs for inducing immune responses |
-
1996
- 1996-12-24 JP JP35617996A patent/JP3340928B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JPH10182410A (en) | 1998-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100833805B1 (en) | Cosmetic composition | |
| JPH0967401A (en) | Tocopherylglycosides, method for preparing them, and their use as surfactants, antioxidants and active substances whichprevent cell from aging in cosmetics or pharmaceutical preparations | |
| JP2002003363A (en) | Cosmetic composition | |
| JP3340935B2 (en) | Melanin production inhibitor and whitening cosmetic | |
| JP3340928B2 (en) | Melanin production inhibitor and whitening cosmetic | |
| JP3271840B2 (en) | Novel isoflavone glycosides and cosmetics containing the same | |
| JP4856809B2 (en) | Topical skin preparation | |
| JP3192376B2 (en) | Melanin production inhibitor and whitening cosmetic | |
| JPH10175820A (en) | Suppressant for melanogenesis and beautifying and whitening cosmetic | |
| JP3340930B2 (en) | Melanin production inhibitor and whitening cosmetic | |
| JP2004115381A (en) | External preparation for skin | |
| JP2010037251A (en) | Skin external preparation | |
| JP3034057B2 (en) | Sugar-cinnamic acid derivatives and UV absorbers | |
| JP2000290177A (en) | Nitrogen monoxide scavenger and aging-protecting cosmetic material | |
| JPH0580449B2 (en) | ||
| JP3007171B2 (en) | Sugar-cinnamic acid derivatives and UV absorbers | |
| JP3976943B2 (en) | Whitening cosmetics | |
| JP2006225359A (en) | Whitening cosmetics | |
| JPH0977660A (en) | Melanogenesis suppressing agent and skin preparation for external use | |
| JPH09132527A (en) | Suppressant for melanogenesis and dermal preparation for external use | |
| JP2000095641A (en) | Bleaching preparation | |
| JPH04261115A (en) | External agent for skin | |
| JPH09241128A (en) | Tyrosinase activity inhibitor | |
| JPH09301990A (en) | Sesamol glucide and preparation for external use for skin | |
| JP3140575B2 (en) | Benzophenone derivative, ultraviolet absorber and external skin preparation containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090816 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100816 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100816 Year of fee payment: 8 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100816 Year of fee payment: 8 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110816 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110816 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120816 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120816 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130816 Year of fee payment: 11 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |